

Drug Mifegymiso added to the Alberta Public Health Activities Program (APHAP) Women's Choice Program

Effective **July 24, 2017**, Alberta Health is introducing the Women's Choice Program, which will be providing coverage for Mifegymiso through licensed pharmacies in Alberta to allow women to exercise their choice in sexual health. Alberta Blue Cross is facilitating payment of claims for Mifegymiso under this program.

Mifegymiso, a combination product containing mifepristone and misoprostol, is indicated for medical termination of a developing intrauterine pregnancy.

Program participation and benefit eligibility

For an Albertan to be eligible to receive coverage through the Women's Choice Program, at no charge to them, they must

- be registered with the Alberta Health Care Insurance Plan and have a valid Personal Health Number (PHN);
 - a pseudo PHN of WC0000000 is eligible for Albertans without a valid PHN.
- be the subject of a valid prescription for Mifegymiso.

Claim processes

When billing claims for the eligible product, Alberta Blue Cross requires that the claims be submitted electronically through the Alberta Blue Cross PRIDE-RT direct bill claim adjudication system with the following claim data elements:

- Carrier Code: 16 (Alberta Public Health Activities Program (APHAP))
- Group number for all transactions must be 23464, Section 000
- Pharmacy License number
- Pharmacist Identification Number
- Plan member number: plan member's personal health number (PHN)
- In the case of Albertans with no PHN, WC0000000 must be used and record of confirmation of Alberta residency should be kept on file. Women who do not reside in Alberta may be charged for the drug product.
- Plan member's full name: last and first name
- Plan member's date of birth
- Plan member's gender
- Relationship code: should your software require you to enter a relationship code, zero (0) must be used as the default
- Prescriber Reference ID Number
- Service Date
- DIN (for Mifegymiso as seen below)
- Quantity
- "81" should be used in the Prescriber Reference Code field

The following product is eligible for coverage effective July 24, 2017.

... continued from previous page

DIN	Product Description	Unit of Issue	Unit Price	Allowable Upcharge #1	Allowable Upcharge #2	Dispensing Fee
02444038	Mifegymiso 200 mg/200 mcg Buccal Tablet	Tablet	\$60.00 per tablet Claim to be submitted as a quantity of 5 tablets. Package price = \$300.00, plus Allowable Upcharges.	7.5%	7%	\$12.30

One dose of Mifegymiso consists of one combination pack containing one mifepristone tablet and four buccal misoprostol tablets. There is no limit on the number of Mifegymiso prescriptions that a plan member may receive under the Women's Choice Program; however, pharmacies may only claim one dose at a time for a plan member.

The program provides for direct bill claims submission only. Plan members are not eligible to claim for reimbursement.

Product stock

Mifegymiso is not currently stocked by McKesson; however, the Canadian distributor of Mifegymiso, Celopharma Inc, has a drop ship program in place with McKesson. If Mifegymiso is ordered through McKesson, Celopharma will ship the product directly to the pharmacy.

Mifegymiso is also available directly from Celopharma by emailing celopharma@lsu3pl.ca. Celopharma will ship the product directly to the pharmacy and invoice the pharmacy directly.

There is no minimum order for Mifegymiso. The delivery time may be up to four days.

Pharmacists will be reimbursed according to the Alberta Pharmaceutical Services Provider Agreement.

Further information

The Alberta College of Pharmacists has provided guidelines for dispensing Mifegymiso (available at <https://pharmacists.ab.ca/guidelines-dispensing-mifegymiso>), aligned to the position of The College of Physicians and Surgeons of Alberta published in its June 5, 2017 online newsletter at <http://www.cpsa.ca/trevors-take-on-leaving-the-college>. The guidance specifies that dispensing pharmacists must dispense Mifegymiso in the manner detailed by the prescribing physician on the prescription (i.e. to the person subject of the prescription **or** to the prescribing physician, as specified).

Pharmacists are encouraged to complete module 5 of either the accredited (paid access) or non-accredited (free access) Medical Abortion Training Program developed by the Society of Obstetricians and Gynaecologists of Canada (SOGC) in collaboration with the College of Family Physicians of Canada (CFPC) and the Canadian Pharmacists Association (CPhA). These courses are accessible at <https://sogc.org/online-courses/courses.html>. (Medical Abortion Training Program)

Supports and resources for physicians and other professionals who facilitate access to Mifegymiso are available through the Canadian Abortion Providers Support (CAPS) at https://www.caps-cpca.ubc.ca/index.php/Main_Page.

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit <https://www.ab.bluecross.ca/providers/pharmacy-home.php>



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.697 2017/07

